SCHEMBL2094064

SCHEMBL2094064

CCOC(=O)NCc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 5/20 0.60
PPARG P37231 2/20 0.60
PPARA Q07869 2/20 0.60
NR1H4 Q96RI1 1/20 0.58
POLB P06746 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.54
TSHR P16473 1/20 0.54
HTR2C P28335 3/20 0.50
GLA P06280 1/20 0.50
KMT2A Q03164 1/20 0.50
LMNA P02545 1/20 0.49
GAA P10253 1/20 0.49
ALDH1A1 P00352 2/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2D6 P10635 2/20 0.48
CYP2C9 P11712 2/20 0.48
HPGD P15428 2/20 0.48
CYP2C19 P33261 2/20 0.48
ADRB2 P07550 1/20 0.48
PDE2A O00408 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27859550 0.86 EPHX2 (0.62) EPHX2PPARGPPARANR1H4SMN1; SMN2
SCHEMBL15682711 0.86 EPHX2 (0.58) EPHX2PPARGPPARANR1H4POLB
SCHEMBL793534 0.86 GLA (0.70) EPHX2PPARGPPARANR1H4POLB
SCHEMBL10599026 0.84 TSHR (0.70) SMN1; SMN2TSHRGLAKMT2ALMNA
SCHEMBL6635990 0.83 EPHX2 (0.61) EPHX2PPARGPPARANR1H4SMN1; SMN2
SCHEMBL2087780 0.82 FAAH (0.49) EPHX2PPARGPPARANR1H4HTR2C
SCHEMBL934006 0.82 EPHX2 (0.60) EPHX2PPARGPPARANR1H4SMN1; SMN2
SCHEMBL3966634 0.81 EPHX2 (0.63) EPHX2PPARGPPARANR1H4POLB
SCHEMBL933617 0.79 EPHX2 (0.58) EPHX2PPARGPPARANR1H4HTR2C
SCHEMBL2723278 0.79 FAAH (0.57) EPHX2PPARGPPARANR1H4POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 EPHX2 3472/4885PPARG 457/4885PPARA 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.